M
Maureen E. Trudeau
Researcher at Sunnybrook Health Sciences Centre
Publications - 259
Citations - 14303
Maureen E. Trudeau is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 51, co-authored 235 publications receiving 12424 citations. Previous affiliations of Maureen E. Trudeau include York University & Women's College Hospital.
Papers
More filters
Journal ArticleDOI
178pgeneration of a plasma microrna (mirna) signature predicting response to metronomic chemotherapy (mc) for advanced breast cancer (abc)
Urban Emmenegger,Berta Sousa,V.C. Hoang,Annabelle Chow,Mark Clemons,Susan Dent,Nan Soon Wong,Robert S. Kerbel,Maureen E. Trudeau,J. Slingerland,Andrea Eisen,John M.L. Ebos,Kelvin K. W. Chan,Sandra Gardner,Kathleen I. Pritchard +14 more
TL;DR: The first candidate miRNA signature predicting response to MC is described, currently being validated in the original and extension dalCMP study populations (n = 92), and may become a helpful tool to select patients with ABC suitable for dal CMP, and to possibly predict response to other MC regimens as well as to MC used for other tumor types.
Journal ArticleDOI
Radiation recall dermatitis with abemaciclib developing a year after radiotherapy
Archya Dasgupta,Archya Dasgupta,Archya Dasgupta,Francis Patafio,Hany Soliman,Hany Soliman,Hany Soliman,Arjun Sahgal,Arjun Sahgal,Arjun Sahgal,Maureen E. Trudeau,Maureen E. Trudeau,Gregory J. Czarnota +12 more
TL;DR: This is the first incidence of RRD with the use of a CDK4/6 inhibitor upon switching to abemaciclib (receiving reduced dose) from palbociclib.
Journal ArticleDOI
776P Early mortality in patients with cancer treated with immunotherapy in routine practice
Jacques Raphael,L Richard,M. Lam,Phillip Blanchette,NB Leighl,G. Rodrigues,Maureen E. Trudeau,Monika K. Krzyzanowska +7 more
TL;DR: Early cross-over of Kaplan-Meier survival curves seen in clinical trials of immunotherapy (IO) suggests that some patients with cancer treated with IO are at risk for early mortality as discussed by the authors .
Journal ArticleDOI
Outcomes of patients with T1a,b N0 Her2-positive breast cancer treated with adjuvant trastuzumab in a prospective registry in Ontario, Canada.
Andrea Eisen,Tripat Gill,Steven Habbous,Jaclyn Beca,Jessica Arias,Kelvin Chan,Maureen E. Trudeau +6 more
TL;DR: Analysis of the Ontario EBP for pts with, T1a,b N0 HER2 pos BrCa revealed that the prognosis is excellent and is improved with the use of chemo + tras, and the safety profile was expected and tolerable, especially when non anthracycline chemo was used.
Journal ArticleDOI
Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice.
Jacques Raphael,Lucie Richard,Melody Lam,Phillip Blanchette,Natasha B. Leighl,George Rodrigues,Maureen E. Trudeau,Monika K. Krzyzanowska +7 more
TL;DR: In this paper , the proportion of patients with cancer treated with immune checkpoint inhibitors (ICI) who die soon after starting ICI in the real world and to examine factors associated with early mortality (EM).